Predict your next investment

Private Equity
staleycapital.com

See what CB Insights has to offer

Investments

10

Portfolio Exits

2

Funds

2

Service Providers

1

About Staley Capital Advisers

The Staley Capital team is passionate about backing great management teams in growth services companies that offer compelling, demonstrable and innovative value propositions in vertical markets the team understands deeply.

Staley Capital Advisers Headquarter Location

950 Winter Street, Suite 1701

Waltham, Massachusetts, 02451,

United States

781-487-2222

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Staley Capital Advisers News

Staley Capital Advisers Inc. Has $314,000 Stake in Merck & Co. (MRK)

Sep 18, 2016

Tweet Staley Capital Advisers Inc. continued to hold its position in shares of Merck & Co. (NYSE:MRK) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,454 shares of the company’s stock at the end of the second quarter. Staley Capital Advisers Inc.’s holdings in Merck & Co. were worth $314,000 as of its most recent SEC filing. Several other institutional investors have also made changes to their positions in MRK. Americafirst Capital Management LLC acquired a new position in shares of Merck & Co. during the second quarter worth about $115,000. NewSquare Capital LLC boosted its position in shares of Merck & Co. by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock worth $121,000 after buying an additional 261 shares in the last quarter. First New York Securities LLC NY acquired a new position in shares of Merck & Co. during the second quarter worth about $121,000. Lowe fs LLC boosted its position in shares of Merck & Co. by 1.8% in the second quarter. Lowe fs LLC now owns 2,619 shares of the company’s stock worth $151,000 after buying an additional 46 shares in the last quarter. Finally, JNBA Financial Advisors boosted its position in shares of Merck & Co. by 3.1% in the second quarter. JNBA Financial Advisors now owns 3,012 shares of the company’s stock worth $174,000 after buying an additional 91 shares in the last quarter. Institutional investors own 72.94% of the company’s stock. Shares of Merck & Co. ( NYSE:MRK ) traded down 0.16% during mid-day trading on Friday, hitting $62.28. 12,432,293 shares of the company were exchanged. The firm has a 50 day moving average of $61.95 and a 200 day moving average of $57.17. Merck & Co. has a 12-month low of $47.97 and a 12-month high of $64.00. The company has a market capitalization of $172.22 billion, a price-to-earnings ratio of 34.16 and a beta of 0.63. Merck & Co. (NYSE:MRK) last posted its quarterly earnings results on Friday, July 29th. The company reported $0.93 EPS for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.02. The business earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. Merck & Co.’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.86 earnings per share. Equities research analysts forecast that Merck & Co. will post $3.75 earnings per share for the current year. The business also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be paid a $0.46 dividend. This represents a $1.84 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date is Tuesday, September 13th. Merck & Co.’s dividend payout ratio (DPR) is presently 101.10%. A number of equities analysts have recently issued reports on MRK shares. Vetr upgraded shares of Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 price objective for the company in a research note on Monday, July 4th. Argus restated a “buy” rating on shares of Merck & Co. in a research note on Thursday, June 9th. Jefferies Group increased their price objective on shares of Merck & Co. from $50.00 to $53.00 and gave the company a “hold” rating in a research note on Thursday, July 14th. Leerink Swann restated a “hold” rating and issued a $58.00 price objective on shares of Merck & Co. in a research note on Thursday, July 14th. Finally, Credit Suisse Group AG restated a “hold” rating and issued a $59.00 price objective on shares of Merck & Co. in a research note on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of €63.31 ($70.34). In other Merck & Co. news, EVP Clark Golestani sold 3,000 shares of the business’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of €63.03 ($70.03), for a total transaction of €189,090.00 ($210,100.00). The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Also, EVP Adam H. Schechter sold 39,200 shares of the business’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of €62.61 ($69.57), for a total value of €2,454,312.00 ($2,727,013.33). Following the transaction, the executive vice president now directly owns 39,200 shares of the company’s stock, valued at approximately €2,454,312 ($2,727,013.33). The disclosure for this sale can be found here . 0.05% of the stock is owned by corporate insiders. Merck & Co. Company Profile Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK). Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter . Comment on this Post

Staley Capital Advisers Investments

10 Investments

Staley Capital Advisers has made 10 investments. Their latest investment was in Aspire Marketing Services as part of their Private Equity on August 8, 2019.

CBI Logo

Staley Capital Advisers Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/7/2019

Private Equity

Aspire Marketing Services

Yes

1

2/5/2018

Recap

Smart Action

Yes

5

7/28/2016

Series C

Yieldbot

$35M

Yes

13

12/10/2015

Series D

Subscribe to see more

$99M

Subscribe to see more

10

9/17/2007

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/7/2019

2/5/2018

7/28/2016

12/10/2015

9/17/2007

Round

Private Equity

Recap

Series C

Series D

Series B

Company

Aspire Marketing Services

Smart Action

Yieldbot

Subscribe to see more

Subscribe to see more

Amount

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

5

13

10

10

Staley Capital Advisers Portfolio Exits

2 Portfolio Exits

Staley Capital Advisers has 2 portfolio exits. Their latest portfolio exit was Acclaris on May 11, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/11/2015

Acquired

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

5/11/2015

00/00/0000

Exit

Acquired

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Sources

2

10

Staley Capital Advisers Acquisitions

1 Acquisition

Staley Capital Advisers acquired 1 company. Their latest acquisition was Acclaris on July 07, 2010.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/7/2010

Series B

$14.25M

Acq - Fin

Date

7/7/2010

Investment Stage

Series B

Companies

Valuation

Total Funding

$14.25M

Note

Acq - Fin

Sources

Staley Capital Advisers Fund History

2 Fund Histories

Staley Capital Advisers has 2 funds, including Staley Capital Fund I LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/7/2010

Staley Capital Fund I LP

Multi-Stage Venture Capital

$21M

1

Staley Capital Fund II LP

Subscribe to see more

$99M

10

Closing Date

4/7/2010

Fund

Staley Capital Fund I LP

Staley Capital Fund II LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Status

Amount

$21M

$99M

Sources

1

10

Staley Capital Advisers Service Providers

1 Service Provider

Staley Capital Advisers has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Staley Capital Advisers Team

8 Team Members

Staley Capital Advisers has 8 team members, including current Chief Executive Officer, President, John Adolphus Staley.

Name

Work History

Title

Status

John Adolphus Staley

Chief Executive Officer, President

Current

Jeffrey M Hurst

Managing Partner

Current

Renny Smith

Thomas H. Lee Partners, TH Lee Putnam Ventures, and Merrill

Managing Partner

Current

Michael Friday

Managing Director

Current

Brian Michael Mcinerney

Managing Director

Current

Name

John Adolphus Staley

Jeffrey M Hurst

Renny Smith

Michael Friday

Brian Michael Mcinerney

Work History

Thomas H. Lee Partners, TH Lee Putnam Ventures, and Merrill

Title

Chief Executive Officer, President

Managing Partner

Managing Partner

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.